Literature DB >> 17805332

The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells.

I Ringshausen, M Oelsner, C Bogner, C Peschel, T Decker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17805332     DOI： 10.1038/sj.leu.2404922

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

Review 1.  Oral Therapies for Multiple Sclerosis.

Authors:  Simon Faissner; Ralf Gold
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

2.  Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.

Authors:  Numsen Hail; Ping Chen; Lane R Bushman
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

3.  The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms.

Authors:  Emel Koseoglu; Neslihan Sungur; Sabahattin Muhtaroglu; Gokmen Zararsiz; Ahmet Eken
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

4.  Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.

Authors:  Yash Somnay; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Neuroendocrinology       Date:  2012-09-04       Impact factor: 4.914

5.  Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.

Authors:  Michael Rosenzweig; Joycelynne Palmer; Ni-Chun Tsai; Tim Synold; Xiwei Wu; Shu Tao; Samantha N Hammond; Ralf Buettner; Lupe Duarte; Myo Htut; Chatchada Karanes; Nitya Nathwani; Flavia Pichiorri; Firoozeh Sahebi; James F Sanchez; Arnab Chowdhury; Amrita Krishnan; Stephen J Forman; Steven T Rosen
Journal:  Leuk Lymphoma       Date:  2020-04-08

6.  Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.

Authors:  Ou Huang; Weili Zhang; Qiaoming Zhi; Xiaofeng Xue; Hongchun Liu; Daoming Shen; Meiyu Geng; Zuoquan Xie; Min Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-10

7.  Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.

Authors:  Mackenzie R Cook; Scott N Pinchot; Renata Jaskula-Sztul; Jie Luo; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2010-01-26       Impact factor: 6.261

8.  Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells.

Authors:  Yasaman KalantarMotamedi; Fatemeh Ejeian; Faezeh Sabouhi; Leila Bahmani; Alireza Shoaraye Nejati; Aditya Mukund Bhagwat; Ali Mohammad Ahadi; Azita Parvaneh Tafreshi; Mohammad Hossein Nasr-Esfahani; Andreas Bender
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

9.  Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.

Authors:  Juliana Vélez; Numsen Hail; Marina Konopleva; Zhihong Zeng; Kensuke Kojima; Ismael Samudio; Michael Andreeff
Journal:  Front Oncol       Date:  2013-04-02       Impact factor: 6.244

10.  Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo.

Authors:  Shunqin Zhu; Xiaomin Yan; Zhonghuai Xiang; Han-Fei Ding; Hongjuan Cui
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.